Holen Sie sich die Stockscreener-App
264.88
2.37%
-6.426
Handel nachbörslich:
264.91
0.026
+0.01%
Schlusskurs vom Vortag:
$271.31
Offen:
$268.18
24-Stunden-Volumen:
1.48M
Relative Volume:
2.06
Marktkapitalisierung:
$18.63B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
80.61
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
-6.81%
1M Leistung:
-8.23%
6M Leistung:
-8.73%
1J Leistung:
-3.99%
1-Tages-Spanne:
$261.95
$270.61
1-Wochen-Bereich:
$261.95
$288.98
52-Wochen-Spanne:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
264.88 | 19.09B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Ownership Capital B.V. Sells 103,193 Shares of Insulet Corporation $PODD - MarketBeat
Pier 88 Investment Partners LLC Raises Stock Position in Insulet Corporation $PODD - MarketBeat
Cowen assumes coverage on Insulet stock with Hold rating - Investing.com
Strs Ohio Has $5.15 Million Position in Insulet Corporation $PODD - MarketBeat
Published on: 2026-01-27 12:20:42 - baoquankhu1.vn
Here's Why Insulet (PODD) is a Strong Growth Stock - Nasdaq
Y Intercept Hong Kong Ltd Sells 9,830 Shares of Insulet Corporation $PODD - MarketBeat
How (PODD) Movements Inform Risk Allocation Models - Stock Traders Daily
Insulet Corporation $PODD Shares Sold by Teacher Retirement System of Texas - MarketBeat
Insulet Corporation $PODD Shares Sold by Baillie Gifford & Co. - MarketBeat
Insulet Stock Is Going Off: Game-Changer Buy Or Overhyped Trap? - AD HOC NEWS
Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Insulet Completes Key Omnipod 5 SmartAdjust 2.0 Study, Setting Up Next Growth Phase - TipRanks
What You Need To Know Ahead of Insulet’s Earnings Release - Barchart.com
Universal Beteiligungs und Servicegesellschaft mbH Sells 4,979,945 Shares of Insulet Corporation $PODD - MarketBeat
BVI appoints Jim Hollingshead as CEO - MedTech Dive
SG Americas Securities LLC Has $831,000 Stock Holdings in Insulet Corporation $PODD - MarketBeat
Is Insulet (PODD) the Future of Diabetes Management? - Nasdaq
VIX Spike: Is Insulet Corporation a play on infrastructure spendingRecession Risk & Fast Gain Stock Tips - baoquankhu1.vn
BVI Appoints Jim Hollingshead as President & Chief Executive Officer - GlobeNewswire Inc.
PODD stock benefits from FDA approval of Omnipod 5's enhancements - MSN
Chart Watch: What drives SWAGWs stock priceWeekly Stock Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
Insulet Corporation $PODD Shares Purchased by Stephens Investment Management Group LLC - MarketBeat
Goldman Sachs Adjusts Price Target on Insulet to $363 From $365, Maintains Buy Rating - marketscreener.com
Nisa Investment Advisors LLC Sells 4,201 Shares of Insulet Corporation $PODD - MarketBeat
Wells Fargo Sticks to Their Buy Rating for Insulet (PODD) - The Globe and Mail
Bernstein Reduces Firm's PT on Insulet (PODD) Stock - Finviz
Bernstein Reduces Firm’s PT on Insulet (PODD) Stock - Insider Monkey
Bernstein reduces firm’s PT on Insulet (PODD) stock - MSN
Nordea Investment Management AB Has $125.13 Million Position in Insulet Corporation $PODD - MarketBeat
Insulet Corp (NASDAQ:PODD) Passes Key Growth Screen with Strong Momentum - Chartmill
Insulet Stock Is Going Off: Game-Changer For Diabetes Tech Or Just Hype? - AD HOC NEWS
Investment Recap: Will Insulet Corporation stock benefit from AI adoptionPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Trading Systems Reacting to (PODD) Volatility - Stock Traders Daily
Insulet Corporation (PODD) Stock Analysis: A 29.95% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Insulet Shares Fall After Barclays Downgrade - marketscreener.com
Barclays downgrades Insulet stock rating to Underweight on competition concerns - Investing.com
Insulet (PODD) Downgraded by Barclays with Lowered Price Target - GuruFocus
Barclays Downgrades Insulet to Underweight From Equal Weight, Adjusts Price Target to $274 From $316 - marketscreener.com
Barclays downgrades DexCom, Insulet as diabetes competition seen intensifying in 2 - Investing.com
Insulet (PODD) Downgraded by Barclays Amid Growing Competition - GuruFocus
Barclays Downgrades Insulet Corporation (PODD) to Underweight - StreetInsider
Insulet (NASDAQ:PODD) Downgraded to Equal Weight Rating by Barclays - MarketBeat
Aug Movers: Can Insulet Corporation ride the EV waveJuly 2025 Sentiment & High Return Trade Guides - baoquankhu1.vn
Insulin Patch Pump Market Is Going to Boom | Medtronic • Insulet Corporation • Tandem Diabetes Care - openPR.com
Why Analysts See The Insulet (PODD) Story Shifting As Omnipod Growth Meets Valuation Questions - Yahoo Finance
150,699 Shares in Insulet Corporation $PODD Bought by Parnassus Investments LLC - MarketBeat
Bernstein Lowers Price Target for Insulet (PODD) to $380, Mainta - GuruFocus
Assessing Insulet (PODD) Valuation After CES 2026 Spotlight On Omnipod 5 And Growth Prospects - Sahm
Precision Medicine and the Tubeless Revolution: An In-Depth Look at Insulet Corporation (PODD) - FinancialContent
Bernstein Adjusts Price Target on Insulet to $380 From $410, Maintains Outperform Rating - marketscreener.com
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.02%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):